Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
AIDS expert to head $5-million research efforts on hepatitis C

Health Minister Terry Lake on Thursday announced a $5-million study that will look at how to reduce the spread of hepatitis C among intravenous drug users, sex workers and men who have sex with men. It will concentrate on people who have already taken medication that clears them of the hepatitis C virus, but who could be reinfected if they have blood-to-blood contact with another person. They will be encouraged to prevent that by using condoms, not sharing needles and taking part in support programs through Vancouver Coastal Health, one of the five organizations involved in the program.

Published
22 April 2016
From
Vancouver Sun
Interferon-based therapy improves clinical outcomes in hepatitis delta infection

Patients with hepatitis delta virus infection treated with pegylated interferon alpha were less likely to develop clinical outcomes — like decompensation or hepatocellular carcinoma — compared with patients who received nucleos(t)ide based treatment or no treatment at all, according to a presentation at International Liver Congress.

Published
22 April 2016
From
Healio
DAAs achieve excellent outcomes in real-world settings

Hepatitis C virus (HCV) therapy with direct acting antivirals (DAAs) is as effective in real-world settings as it was in clinical trials, according to US research presented

Published
21 April 2016
By
Michael Carter
High incidence of HCV reinfection among HIV-positive MSM in Western Europe

There is a very high incidence of hepatitis C virus (HCV) reinfection among HIV-positive men who have sex with men (MSM) in western Europe, according to research

Published
19 April 2016
By
Michael Carter
Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection

A dual regimen of sofosbuvir plus velpatasvir was well tolerated and highly effective against hepatitis C virus (HCV) genotypes 1 through 4 in HIV-positive people with chronic

Published
19 April 2016
By
Liz Highleyman
Hepatitis C: no more treatment rationing; universal access to generic medicines everywhere!

People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines. They are pushing for generic competition to bring down the price of HCV treatment and ensure universal access.

Published
18 April 2016
From
Treatment Action Group
Six weeks of sofosbuvir/ledipasvir is enough to cure acute hepatitis C in HIV-negative people

A regimen of sofosbuvir/ledipasvir (Harvoni) taken for six weeks cured all patients with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads,

Published
18 April 2016
By
Liz Highleyman
Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys

The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with fewer detrimental effects

Published
18 April 2016
By
Liz Highleyman
Low-cost generic hepatitis C drugs match branded products in viral response

Generic versions of direct-acting antivirals purchased from China and India by people unable to obtain treatment in their own countries were just as effective and safe as

Published
16 April 2016
By
Keith Alcorn
Shifting hepatitis C treatment to primary care providers could expand availability

Hepatitis C treatment managed by non-specialists such as primary care physicians and nurse practitioners is as safe and effective as treatment delivered by specialists and could help

Published
15 April 2016
By
Liz Highleyman

Filter by country